“Second-line treatment with Axitinib: an effective and well-tolerated weapon in the therapeutic sequence of clear cell renal cell carcinoma”, Work Paper Public Hlth, vol. 4, no. 1, Jun. 2015, doi: 10.4081/wpph.2015.6697.